No, Keflex (cephalexin) is NOT appropriate for this E. coli infection
This resistance pattern indicates an ESBL-producing organism, and cephalexin will not be effective despite cefoxitin susceptibility. The susceptibility to cefoxitin with resistance to third-generation cephalosporins (ceftriaxone, cefpodoxime, cefepime) is the classic laboratory signature of ESBL production in E. coli 1.
Understanding the Resistance Pattern
Your MIC results show:
- Cefoxitin: Susceptible (a second-generation cephamycin)
- Resistant to: Cefazolin (1st gen), Cefepime (4th gen), Cefpodoxime (3rd gen oral), Ceftriaxone (3rd gen IV)
This pattern defines a third-generation cephalosporin-resistant Enterobacterales (3GCephRE), which is presumed ESBL-producing until proven otherwise.
Why Cephalexin Won't Work
Cephalexin is a first-generation oral cephalosporin that is even MORE susceptible to ESBL enzymes than the agents already showing resistance. If the organism is resistant to cefazolin (first-generation IV cephalosporin), it will absolutely be resistant to cephalexin, which has similar or inferior activity 2, 3.
The FDA label for Keflex explicitly lists E. coli as a susceptible organism only when the strain is truly susceptible—not when ESBL mechanisms are present 2.
Critical Pitfall: The Cefoxitin Paradox
Do not be misled by cefoxitin susceptibility. While cefoxitin shows in vitro activity against some ESBL producers due to its relative stability against certain beta-lactamases 4, current guidelines explicitly recommend AGAINST using cephamycins like cefoxitin for 3GCephRE infections 1. The guideline states: "We suggest that cephamycins (e.g. cefoxitin, cefmetazole, flomoxef) and cefepime not be used for 3GCephRE infections" (Conditional recommendation, Very low quality evidence).
Appropriate Treatment Options
For this ESBL-producing E. coli, your treatment choice depends on infection severity:
For Severe Infections (BSI, sepsis, complicated infections):
- Carbapenem therapy is strongly recommended: meropenem or imipenem 1
- Ertapenem may be used for bloodstream infections without septic shock 1
For Non-Severe Urinary Tract Infections:
- Aminoglycosides (if susceptible, short duration) 1
- IV fosfomycin (if available and susceptible) 1
- Piperacillin-tazobactam, amoxicillin-clavulanate, or fluoroquinolones may be considered for low-risk infections under antibiotic stewardship principles, but only if susceptibility is confirmed 1
What About Oral Step-Down?
If you need oral therapy after clinical stabilization, options include:
- Fluoroquinolones (if susceptible)
- Trimethoprim-sulfamethoxazole (if susceptible)
- NOT cephalexin or any oral cephalosporin, as research shows poor correlation between cefoxitin susceptibility and oral cephalosporin efficacy in ESBL producers 5, 6
Bottom Line
Obtain full susceptibility testing immediately and consult infectious disease if available 7. This organism requires carbapenem therapy for serious infections or carefully selected alternatives based on complete susceptibility data for non-severe infections. Cephalexin has no role in treating this resistant E. coli strain.